<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598893</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-031-003</org_study_id>
    <nct_id>NCT04598893</nct_id>
  </id_info>
  <brief_title>Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab</brief_title>
  <official_title>A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provention Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provention Bio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-interventional extension study is to continue to collect long-term&#xD;
      safety and other clinical data for an additional 42 months in participants who completed the&#xD;
      PROTECT study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is the long-term extension of the PRV-031-001 (PROTECT) study. PROTECT is a Phase&#xD;
      3, randomized, double-blind, placebo-controlled, multinational, multi-center study to&#xD;
      evaluate the efficacy and safety of teplizumab, a humanized, anti-CD3 monoclonal antibody, in&#xD;
      children and adolescents ages 8 through 17 recently diagnosed with type 1 diabetes (within 6&#xD;
      weeks of diagnosis). Approximately 300 participants will be randomized at a ratio of 2:1 to&#xD;
      the teplizumab or placebo and will receive two courses of treatment administered 6 months&#xD;
      apart with final follow-up at approximately 18 months (78 weeks) after the first dose.&#xD;
&#xD;
      Participants who complete the PROTECT study are invited to enroll in this observational,&#xD;
      extension study to collect long-term safety and other clinical data. The decision to&#xD;
      participate can be made within 6 months of completing the PROTECT study.&#xD;
&#xD;
      No study drug will be administered during this extension study. Participants will continue to&#xD;
      receive standard care for type 1 diabetes from their primary physicians.&#xD;
&#xD;
      Participants will return to the study sites for assessments once every 6 months through Month&#xD;
      42. Therefore, the combined duration of the PROTECT and PROTECT Extension studies will be 60&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies.</measure>
    <time_frame>42 months of follow-up</time_frame>
    <description>Safety endpoints will be presented descriptively</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Teplizumab</arm_group_label>
    <description>Participants who received teplizumab in the PROTECT study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <description>Participants who received placebo in the PROTECT study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Teplizumab</intervention_name>
    <description>Received teplizumab in PROTECT Study</description>
    <arm_group_label>Teplizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Received placebo in PROTECT study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who completed the PROTECT (PRV-031-001) study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completion of the PRV-031-001 (PROTECT) study by completing the Week 78 visit in that&#xD;
             study, regardless of how many doses of study drug were administered.&#xD;
&#xD;
          2. Provide written informed consent within 6 months of the Week 78 in the PRV-031-001&#xD;
             study. Written assent will be obtained for participants under 18 years of age at the&#xD;
             time of enrollment, according to applicable regulations. If possible, written informed&#xD;
             consent and/or assent for the current PROTECT Extension study (PRV-031-003) should be&#xD;
             obtained at the final (Week 78) visit in the PROTECT study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Premature discontinuation from the PRV-031-001 (PROTECT) study for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rady Children's Hospital 3020 Children's Way (Site 840004)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center Gateway Medical Building, 1825 Fourth Street</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research2255 Ygnacio Valley Road, Ste. M (Site 840002)</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>945981</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes - Pediatrics 1775 Aurora Court (Site 840005)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates 1800 Howell Mill Road. Suite 450 (Site 840009)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute 2425 Brookstone Parkway (Site 840006)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research, LLC 3910 Washington Parkway, Suite E (Site 840007)</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UBMD Pediatrics 1001 Main Street, 4th Floor (Site 840010)</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Service Northwest, LLC 929 SW Simpson Ave. Suite 220 (Site 840034)</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia, Division of Endocrinology 3500 Civic Center Blvd., Buerger Center 12th Floor (Site 840021)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AM Diabetes &amp; Endocrinology Center 3025 Kate Bond Rd. (Site 840008)</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center 1500 21st Avenue, Suite 1514, Village At Vanderbilt (Site 840024)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Children's Medical Center of Dallas 1935 Medical District Drive (Site 840033)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center, Benaroya Research Institute 1201 9th Ave, MS: D4-CRP</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol V Uvalu 84, Praha 5 - Motol (Site 203301)</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus Fetscherstrasse 74 (Site 276601)</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hospital on the Bult Janusz-Korczak-Allee 12 (Site 276604)</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Diabetology ul. Raclawicka 129/2U, 02-117 (Site 616802)</name>
      <address>
        <city>Warsaw</city>
        <zip>02-117</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1D, type 1 diabetes, recent-onset type 1 diabetes, teplizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

